IRVINE, Calif., April 9, 2009 (GLOBE NEWSWIRE) -- Alsius Corporation
(Nasdaq:ALUS), the worldwide leader in intravascular temperature management
(IVTM(tm)) therapies for critically ill patients, today announced that its
consolidated financial statements for the fiscal year ended December 31, 2008,
included in the Company's annual report on Form 10-K filed with the Securities
and Exchange Commission on March 31, 2009, contained a going concern
qualification from its independent registered public accounting firm.
This announcement is required by Nasdaq Marketplace Rule 4350(b)(1)(B), which
requires separate disclosure of receipt of an audit opinion containing a going
concern qualification. This announcement does not represent any change or
amendment to the Company's financial statements or to its Annual Report on Form
10-K for the fiscal year ended December 31, 2008.
About Alsius
Alsius, headquartered in Irvine, Calif., is a medical device company that
develops, manufactures and sells proprietary products to precisely control
patient temperature in hospital critical care settings. Controlling body
temperature, through cooling and warming, is becoming the standard of care for
patients in select critical conditions and those undergoing a variety of
surgical procedures. Alsius markets a comprehensive suite of catheter-based
intravascular temperature management products that address the need for
effective, accurate, easy-to-use and cost-effective control of body temperature
in critical care patients. For more information, visit http://www.alsius.com.
The Alsius Corporation logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6072
This press release may contain statements regarding plans and expectations for
the future that constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements other than
statements of historical fact are forward-looking. Such forward looking
statements, based upon the current beliefs and expectations of Alsius'
management, are subject to risks and uncertainties, which could cause actual
results to differ materially from those described in the forward-looking
statements. The information set forth herein should be read in light of such
risks. Additional information concerning such risks and uncertainties are
contained in Alsius' filings with the Securities and Exchange Commission, which
can be accessed electronically on the Securities and Exchange Commission website
at http://www.sec.gov.
-0-
CONTACT: Alsius Corporation
Andrew Wade, Vice President Finance
949-453-0150
awade@alsius.com
